Daily NSE closing prices — this stock isn't in the live-tracked universe yet.
NSE Close — 19 Nov 2026
₹178.4
Change
-17.85 (-9.1%)
Open
₹191.95
Prev. Close
₹196.25
Day High
₹198.45
Day Low
₹175.5
Volume Analysis
Traded
157,879
Delivered
85,699
Delivery %
54.28%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹215.69 | ₹207.07 | ₹192.74 | ₹184.12 | ₹169.79 | ₹161.17 | ₹146.84 |
| Fibonacci | ₹207.07 | ₹198.3 | ₹192.89 | ₹184.12 | ₹175.35 | ₹169.94 | ₹161.17 |
| Camarilla | ₹184.71 | ₹182.61 | ₹180.5 | ₹184.12 | ₹176.3 | ₹174.19 | ₹172.09 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
-12.78%
1 Month
—
3 Months
—
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Company Overview
Sector
Healthcare
Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.
TopFund Analysis
Ennature Bio Pharma Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 52/100. The strongest factor is Corporate Governance (100/100), while Institutional Ownership (10/100) is the weakest area to weigh before deciding.
TopFund Score — Fundamentals Quality
52/100 — AverageData confidence: 55/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Corporate Governance
Institutional Ownership
Liquidity
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Board designated five executives as senior management personnel effective 12 November 2026.
Board approved new Articles of Association on 12 November 2026, subject to shareholder and regulatory approvals.
Source: BSE regulatory filings, via Screener.in.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Nov 2026 | |
|---|---|
| Public | 33.33% |
| Promoters | 59.63% |
| FII | 2.44% |
| DII | 4.61% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Ennature Bio Pharma Ltd (this stock) | — | — | — | — |
| Sun Pharmaceutical Ind L | 451,075 | 36.7 | 5.05 | 16.0% |
| Divi S Laboratories Ltd | 294,139 | 86.1 | 16.34 | 16.5% |
| Torrent Pharmaceuticals L | 177,632 | 81.8 | 9.67 | 27.4% |
| Apollo Hospitals Enter. L | 125,893 | 55.6 | 11.86 | 21.5% |
| Laurus Labs Limited | 125,380 | 93.6 | 20.73 | 18.3% |
| Zydus Lifesciences Ltd | 118,693 | 26.2 | 4.27 | 21.2% |
Which Mutual Funds Hold Ennature Bio Pharma Ltd?
Frequently Asked Questions about Ennature Bio Pharma Ltd
Ennature Bio Pharma Ltd (ENNATURE) closed at ₹178.4 on NSE on 19 November 2026, down 17.85 (9.1%) from the previous close.
Ennature Bio Pharma Ltd trades on the NSE (National Stock Exchange of India) under the symbol ENNATURE.
Ennature Bio Pharma Ltd has a TopFund Quality Score of 52/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Ennature Bio Pharma Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.